Team approach to lowering high blood pressure worked even in ‘a tough landscape’
A study is called “really, really important” in showing how teams can induce patients to get their blood pressure under control.
Medical News
STAT+: Influential Democratic think tank pushes plan for government to lower health care costs
Democrats are honing in on health care affordability as a key issue ahead of the midterm elections.
STAT+: Trump administration drops court fight to cap NIH payments for research overhead costs
The Trump administration will not be asking the Supreme Court to take up its fight to slash NIH support for research indirect costs
Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs
A federal judge rejected the Trump administration's bid to dismiss a group of states' lawsuit challenging Robert F. Kennedy Jr.'s restructuring of the Department of Health and Human Services.
Despite uncertainties, Travere’s Filspari emerges as first FDA-approved FSGS treatment
From a negative phase 3 readout and a seemingly tightening regulatory climate to a grueling three-month review extension, Travere has defied the odds, securing Filspari a landmark FDA approval as the first treatment for the rare kidney disease focal segmental glomerulosclerosis (FSGS).
Steven Ubl set to depart after more than a decade as CEO of PhRMA
After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, PhRMA, Steve Ubl will step down as its CEO at the end of the year.
Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant
Japan’s Shionogi is joining the spate of drugmakers to unveil a U.S. manufacturing commitment, albeit under slightly different circumstances than its peers.
Pfizer walks away from 'underutilized' office space in South San Francisco, transitions employees to remote roles
The company is moving out of the building that used to house the headquarters of its 2022-acquired Global Blood Therapeutics.
Biogen settles investor lawsuit over its messaging on failed Alzheimer's drug Aduhelm
Biogen has agreed to a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm.
Amgen CEO netted $24.7M pay package in ‘25 as company’s upward trajectory continued
With a solid year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit firmly in the upper echelons of biopharma CEO pay, though not quite at the level seen by some of his peers in 2025.
J&J's Tremfya retakes TV drug ad spending crown from AbbVie
Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March.
STAT+: Everyone agrees AI scribes are increasing health care costs. No one agrees what to do about it
Behind closed doors, health insurers and hospitals agree that AI scribes are bumping up health care costs. But, they don't agree on a solution.
Opinion: What American hospitals can learn from India about waste
American hospitals see mountains of surgical waste as the cost of infection control. Indian hospitals show that’s not so.
STAT+: A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope
A mother's persistence helps revive an all-but-abandoned drug class and could aid her son and thousands of others with neuromuscular conditions.
Judge refuses to block sending abortion pill by mail for now, but says FDA must finish review
A federal judge Tuesday refused to block filling prescriptions for the abortion pill mifepristone by mail across the U.S. — at least for now.
Scientists map the brain’s hidden wiring using RNA barcodes in major breakthrough
Researchers have developed a cutting-edge technique that uses RNA “barcodes” to map how neurons connect, capturing thousands of links with single-synapse precision. The method transforms brain mapping into a sequencing task, making it faster and more scalable than traditional approaches. In mice, it revealed surprising new connections between brain cells that were previously unknown. This could op
Scientists discover reversible male birth control that stops sperm production
Scientists at Cornell University may be closing in on the long-sought “holy grail” of male contraception: a safe, reversible, nonhormonal method that completely halts sperm production. In a breakthrough mouse study, researchers used a compound called JQ1 to temporarily shut down meiosis—the critical process that produces sperm—without causing lasting harm. After treatment stopped, sperm production
STAT+: Novo Nordisk launches high-dose Wegovy
Insurers score Medicare Advantage wins, the obesity drug race continues, and other biotech news from The Readout
STAT+: States looking to regulate use of chatbots
In this edition of STAT Health Tech: UnitedHealth Group's big bet on AI to transform its operations, venture funding trends, and more
With Gardasil demand shortfall in China, Merck and Zhifei adjust their partnership
The plummeting demand for Merck’s HPV vaccine Gardasil in China has forced the New Jersey drugmaker to rework its arrangement with its partner in the country, Zhifei Biological Products.